MetaCap

Becton Dickinson (BDX) vs ResMed (RMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Becton Dickinson (BDX) has outperformed ResMed (RMD) over the past year, gaining 40.4% versus a loss of 6.0%. Over five years, BDX leads with a +13.2% price change compared with -6.2% for RMD. Becton Dickinson is the larger company by market cap ($57.96 billion vs $33.14 billion), about 1.7 times the size, while ResMed is growing revenue faster (+9.9% vs +8.2%).

On valuation, Becton Dickinson trades at a lower forward P/E (15.0x vs 17.8x for ResMed). ResMed pays a dividend yielding 1.04%, while Becton Dickinson does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 7.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDX+40.44%RMD-6.03%
+47%+8%-31%
Nov 21, 20251 yearNov 20, 2026
BDX+11.59%RMD-9.48%
+20%-16%-52%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDX versus RMD key metrics
MetricBDXRMD
Share price$212.78$235.63
Market cap$57.96B$33.14B
1-day change+0.05%-0.53%
YTD return+39.46%-2.18%
1-year return+40.44%-6.03%
5-year return+13.19%-6.20%
P/E ratio (TTM)42.0521.46
Forward P/E14.9617.82
EPS (TTM)$5.06$10.98
Dividend yield1.99%1.04%
Annual dividend$0.00$2.46
Revenue (latest FY)$21.84B$5.65B
Revenue growth (YoY)+8.24%+9.85%
Net income (latest FY)$1.68B$1.52B
Gross margin45.44%61.06%
Operating margin11.81%33.37%
Net margin7.68%26.94%
52-week high$220.36$277.67
52-week low$140.11$180.27
Distance from 52-week high-3.44%-15.14%
Analyst consensusbuybuy
Avg. price target upside+6.28%+12.18%
Average volume1.80M1.30M
Shares outstanding272.39M140.66M
Employees60,00011,370
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BDX has outperformed RMD by 46.5 percentage points over the past year.
  • Becton Dickinson trades at a higher earnings multiple (42.1x vs 21.5x trailing P/E).
  • ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 7.7 cents for Becton Dickinson.

About Becton Dickinson

BDX stock →

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.

Health Care · Medical/Dental Instruments · 60,000 employees

About ResMed

RMD stock →

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.

Health Care · Medical/Dental Instruments · 11,370 employees

BDX vs RMD FAQ

Which is bigger, Becton Dickinson or ResMed?

Becton Dickinson (BDX) is larger, with a market capitalization of $57.96B compared with $33.14B for ResMed (RMD).

Which stock has performed better over the past year, BDX or RMD?

BDX returned +40.44% over the past 12 months, compared with -6.03% for RMD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BDX or RMD?

RMD has the lower trailing P/E at 21.5, versus 42.1 for BDX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Becton Dickinson or ResMed?

Becton Dickinson has the higher yield at 1.99%, compared with 1.04% for ResMed.

Are Becton Dickinson and ResMed in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons